Charles Schwab’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.94M | Sell |
1,740,794
-60,684
| -3% | -$275K | ﹤0.01% | 2155 |
|
|
2026
Q1 | $8.11M | Buy |
1,801,478
+47,767
| +3% | +$249K | ﹤0.01% | 2202 |
|
|
2025
Q4 | $10.8M | Buy |
1,753,711
+74,811
| +4% | +$542K | ﹤0.01% | 2100 |
|
|
2025
Q3 | $12.1M | Buy |
1,678,900
+342,870
| +26% | +$2.04M | ﹤0.01% | 2021 |
|
|
2025
Q2 | $7.09M | Buy |
1,336,030
+170,635
| +15% | +$1.01M | ﹤0.01% | 2171 |
|
|
2025
Q1 | $10.3M | Buy |
1,165,395
+39,860
| +4% | +$479K | ﹤0.01% | 1935 |
|
|
2024
Q4 | $15.4M | Buy |
1,125,535
+42,233
| +4% | +$779K | ﹤0.01% | 1827 |
|
|
2024
Q3 | $29.7M | Buy |
1,083,302
+41,374
| +4% | +$1.12M | 0.01% | 1464 |
|
|
2024
Q2 | $25.5M | Buy |
1,041,928
+55,462
| +6% | +$1.22M | ﹤0.01% | 1513 |
|
|
2024
Q1 | $21M | Buy |
986,466
+60,307
| +7% | +$1.3M | ﹤0.01% | 1577 |
|
|
2023
Q4 | $17.7M | Buy |
926,159
+41,353
| +5% | +$715K | ﹤0.01% | 1668 |
|
|
2023
Q3 | $14.2M | Buy |
884,806
+24,665
| +3% | +$469K | ﹤0.01% | 1715 |
|
|
2023
Q2 | $19.9M | Sell |
860,141
-10,577
| -1% | -$231K | 0.01% | 1504 |
|
|
2023
Q1 | $20.2M | Buy |
870,718
+30,084
| +4% | +$611K | 0.01% | 1463 |
|
|
2022
Q4 | $12.2M | Buy |
840,634
+4,585
| +0.5% | +$85.4K | ﹤0.01% | 1742 |
|
|
2022
Q3 | $16M | Buy |
836,049
+21,381
| +3% | +$491K | 0.01% | 1540 |
|
|
2022
Q2 | $14.8M | Buy |
814,668
+4,547
| +0.6% | +$94.4K | 0.01% | 1608 |
|
|
2022
Q1 | $20.4M | Buy |
810,121
+17,390
| +2% | +$445K | 0.01% | 1533 |
|
|
2021
Q4 | $21.9M | Sell |
792,731
-7,163
| -0.9% | -$208K | 0.01% | 1510 |
|
|
2021
Q3 | $25.8M | Sell |
799,894
-35,666
| -4% | -$1.18M | 0.01% | 1360 |
|
|
2021
Q2 | $25.6M | Buy |
835,560
+15,082
| +2% | +$436K | 0.01% | 1390 |
|
|
2021
Q1 | $25M | Sell |
820,478
-16,393
| -2% | -$465K | 0.01% | 1351 |
|
|
2020
Q4 | $16.6M | Buy |
836,871
+34,037
| +4% | +$550K | 0.01% | 1536 |
|
|
2020
Q3 | $10.5M | Buy |
802,834
+3,829
| +0.5% | +$48.5K | ﹤0.01% | 1660 |
|
|
2020
Q2 | $9.06M | Sell |
799,005
-28,248
| -3% | -$401K | ﹤0.01% | 1712 |
|
|
2020
Q1 | $11.8M | Buy |
827,253
+81,910
| +11% | +$1.73M | 0.01% | 1351 |
|
|
2019
Q4 | $20.3M | Buy |
745,343
+3,641
| +0.5% | +$100K | 0.01% | 1204 |
|
|
2019
Q3 | $21.2M | Sell |
741,702
-40,446
| -5% | -$1.18M | 0.01% | 1106 |
|
|
2019
Q2 | $21.7M | Buy |
782,148
+5,141
| +0.7% | +$145K | 0.01% | 1079 |
|
|
2019
Q1 | $25.8M | Sell |
777,007
-18,997
| -2% | -$578K | 0.02% | 951 |
|
|
2018
Q4 | $23.1M | Buy |
796,004
+11,893
| +2% | +$428K | 0.02% | 902 |
|
|
2018
Q3 | $36.1M | Buy |
784,111
+16,603
| +2% | +$738K | 0.02% | 715 |
|
|
2018
Q2 | $28.7M | Buy |
767,508
+108,303
| +16% | +$3.66M | 0.02% | 821 |
|
|
2018
Q1 | $19.5M | Sell |
659,205
-1,524
| -0.2% | -$51.6K | 0.02% | 1021 |
|
|
2017
Q4 | $22.7M | Buy |
660,729
+29,797
| +5% | +$1.01M | 0.02% | 901 |
|
|
2017
Q3 | $22.8M | Sell |
630,932
-58,435
| -8% | -$1.67M | 0.02% | 828 |
|
|
2017
Q2 | $17.8M | Sell |
689,367
-9,083
| -1% | -$193K | 0.02% | 951 |
|
|
2017
Q1 | $13.4M | Buy |
698,450
+29,348
| +4% | +$520K | 0.01% | 1099 |
|
|
2016
Q4 | $11.2M | Buy |
669,102
+102,593
| +18% | +$1.86M | 0.01% | 1169 |
|
|
2016
Q3 | $11.7M | Buy |
566,509
+19,931
| +4% | +$506K | 0.01% | 1047 |
|
|
2016
Q2 | $16.7M | Buy |
546,578
+60,723
| +12% | +$2.11M | 0.02% | 743 |
|
|
2016
Q1 | $18.2M | Buy |
485,855
+37,663
| +8% | +$1.42M | 0.02% | 660 |
|
|
2015
Q4 | $19.3M | Buy |
448,192
+147,593
| +49% | +$6.24M | 0.03% | 613 |
|
|
2015
Q3 | $11.3M | Buy |
300,599
+42,247
| +16% | +$1.5M | 0.02% | 916 |
|
|
2015
Q2 | $8.78M | Buy |
258,352
+117,644
| +84% | +$4M | 0.01% | 1146 |
|
|
2015
Q1 | $4.98M | Sell |
140,708
-32,659
| -19% | -$1.17M | 0.01% | 1511 |
|
|
2014
Q4 | $5.91M | Sell |
173,367
-39,405
| -19% | -$1.4M | 0.01% | 1318 |
|
|
2014
Q3 | $8.21M | Buy |
212,772
+4,379
| +2% | +$163K | 0.01% | 974 |
|
|
2014
Q2 | $8.11M | Buy |
208,393
+19,952
| +11% | +$742K | 0.01% | 999 |
|
|
2014
Q1 | $6.44M | Buy |
188,441
+39,807
| +27% | +$1.23M | 0.01% | 1126 |
|
|
2013
Q4 | $3.12M | Buy |
148,634
+35,149
| +31% | +$889K | 0.01% | 1626 |
|
|
2013
Q3 | $2.87M | Buy |
113,485
+11,693
| +11% | +$332K | 0.01% | 1611 |
|
|
2013
Q2 | $2.78M | Buy |
+101,792
| New | +$2.95M | 0.01% | 1528 |
|
Other funds holding MYGN
VPC
Charles Schwab's MYGN Position: Q2 2026 in Review
Charles Schwab reduced its Myriad Genetics (MYGN) stake by 3.4% in Q2 2026, selling an estimated $275K and leaving 1,740,794 shares worth $9.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2155.
Charles Schwab first reported a position in MYGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $36.1M in Q3 2018. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- Charles Schwab held 1,740,794 shares of Myriad Genetics worth $9.94M as of Q2 2026.
- Charles Schwab sold 60,684 Myriad Genetics shares in Q2 2026, an estimated $275K.
- Myriad Genetics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2155 holding.
- Charles Schwab first reported a position in Myriad Genetics in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Myriad Genetics position peaked at $36.1M in Q3 2018.
- 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.